Author:
Abel Samantha,Russell Deborah,Whitlock Lyndsey A.,Ridgway Caroline E.,Nedderman Angus N. R.,Walker Donald K.
Subject
Pharmacology (medical),Pharmacology
Reference7 articles.
1. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
2. SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV
3. 3R Hyland, B Jones, and G MuirheadIn vitroassessment of the CYP-based drug-drug interaction potential of UK-427 857. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 April 1-3; Rome, Italy.
4. 4S Abel, E van der Ryst, MC Rosario, CE Ridgway, CG Medhurst, RJ Taylor-Worth, and GJ Muirhead . Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers . Br J Clin Pharmacol2008 ; 65 (Suppl. 1 ): 5 -18 .
5. 5PLS Chan, B Weatherley, and L McFadyen . A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infect subjects . Br J Clin Pharmacol2008 ; 65 (Suppl. 1 ): 76 -85 .
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献